Drug Information

Drug General Information
Drug ID
D0A8HN
Former ID
DNCL002483
Drug Name
Iboctadekin
Indication Non-hodgkin's lymphoma; Ovarian cancer [ICD9: 183; ICD10:C85, C56] Phase 1 [546479]
Company
GlaxoSmithKline
Target and Pathway
Target(s) Interleukin-18 Target Info Modulator [550351]
KEGG Pathway Cytokine-cytokine receptor interaction
NOD-like receptor signaling pathway
Cytosolic DNA-sensing pathway
Salmonella infection
Legionellosis
African trypanosomiasis
Malaria
Tuberculosis
Influenza A
Inflammatory bowel disease (IBD)
Rheumatoid arthritis
NetPath Pathway IL4 Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Toll receptor signaling pathway
Pathway Interaction Database IL27-mediated signaling events
IL12-mediated signaling events
IL23-mediated signaling events
Cellular roles of Anthrax toxin
IL12 signaling mediated by STAT4
Reactome Interleukin-1 processing
WikiPathways Hypertrophy Model
IL1 and megakaryotyces in obesity
Corticotropin-releasing hormone
NOD pathway
References
Ref 546479Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008435)
Ref 550351Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res. 2013 Sep;1(3):168-78.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.